Posted on 13/01/2010 in Pharmaceutical Company Product News Bayer Schering Pharma has revealed that it successfully completed the procedure for securing approval to use the contrast medium Gadovist 1.0 in children aged seven and over in European countries.
The first nation to distribute the drug will be Germany, which will market it for this indication in January, followed by Switzerland.
Regulatory authorities in the country have approved Gadovist 1.0 for the use in patients aged two years or older.
Gadovist was originally recommended for magnetic resonance tomography examinations in adults, including blood vessel imaging and studies of the central nervous system, liver and kidneys.
Professor Hans Maier, head of diagnostic imaging at Bayer Schering Pharma, said: "We will cooperate with the authorities and will submit further data if requested with the prospect of securing approval for the use of Gadovist 1.0 in children under the age of seven in Europe's main markets."
In December, Bayer revealed that its endometriosis therapy Visanne was approved for marketing in Europe. Other news stories from 13/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
